Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase Ib/II open-label multicenter study of LBL-024 combination therapy in metastatic colorectal cancer
CTR20263309Phase 2Active
- Sponsor
- Leads Biolabs
- Start
- Oct 2026
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of opamtistomig in colorectal cancer (CRC), metastatic colorectal adenocarcinoma (mCRC), sponsored by Leads Biolabs. Started Oct 2026; status: active.
02
Drugs
opamtistomig
03
Conditions
colorectal cancer (CRC)metastatic colorectal adenocarcinoma (mCRC)
Beyond the preview
Go deeper on CTR20263309.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20263309.